Nanobiotix (NASDAQ:NBTX – Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 20th. Analysts expect Nanobiotix to post earnings of ($0.58) per share and revenue of $3.55 million for the quarter.
Nanobiotix Stock Up 5.9%
Shares of NBTX opened at $3.89 on Monday. Nanobiotix has a one year low of $2.76 and a one year high of $7.29. The business has a fifty day moving average of $3.41 and a 200 day moving average of $3.44.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Guggenheim cut their price objective on Nanobiotix from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, April 4th. UBS Group raised Nanobiotix to a “hold” rating in a report on Monday, February 17th.
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
- Five stocks we like better than Nanobiotix
- What Are Treasury Bonds?
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Savvy Investors Are Raising a Glass for Heineken Stock
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
